Table 1.
Clinical characteristics of 1520 eyes of 864 DED patients with or without oGVHD at baseline.
| DED without oGVHD (n=600, 69%) | DED with oGVHD (n=264, 31%) | ||
|---|---|---|---|
| Age, median (range) | 58 (13–98) | 56 (21–75) | |
| Sex | Female (%) | 483 (81%) | 123 (47%) |
| Male (%) | 117 (19%) | 141 (53%) | |
| Punctal Plugs | |||
| Bilateral | 427 (71%) | 228 (86%) | |
| Unilateral | 173 (29%) | 37 (14%) | |
| Use of topical ophthalmic medications (n,%) | |||
| Artificial Tears | 600 (100%) | 264 (100%) | |
| Restasis | 476 (79%) | 259 (98%) | |
| Corticosteroids | 83 (14%) | 109 (41%) | |
| Anti-glaucoma drugs | 60 (10%) | 20 (8%) | |
| Anti-microbial drugs | 37 (6%) | 98 (37%) | |
| Serum Tears | 20 (3%) | 14 (5%) | |
| Use of systemic immunosuppressive drugs | |||
| Corticosteroids | 38 (6%) | 177 (67%) | |
| Tacrolimus | 17 (3%) | 133 (50%) | |
| Cyclosporine | 16 (3%) | 20 (8%) | |
| Mycophenolate | 4 (<1%) | 46 (17%) | |